AVAH
Aveanna Healthcare Holdings Inc.
AVAH's fundamentals are strong: revenue grew 17% and free cash flow more than doubled. At 8.7x earnings, it's trading less than half its usual 21x. Analysts expect that strong growth to continue.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AVAH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Under pressure |
AVAH's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AVAH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.6x | $9.24 | -25% |
| Current | 8.7x | $12.24 | — |
| Forward | 14x | $12.24 | — |
| Fair | 21x | $29.51 | +141% |
| Expensive | 108x | $151 | +1130% |
Historical ranges are pointers, not guarantees.
AVAH's PE is in its cheap range at 8.7x. On analysts' estimates for next year's earnings, today's price would be 14x, in its fair range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AVAH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
AVAH has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AVAH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.88 | -37% |
| Q3 2026 | $1.40 | +278% |
| Q2 2026 | $1.26 | +1300% |
| Q1 2026 | $1.21 | +3933% |
| Q4 2025 | $1.05 | +$1.11 |
| Q3 2025 | $0.37 | +$0.71 |
| Q2 2025 | $0.09 | +$0.75 |
| Q1 2025 | $0.03 | +$0.63 |
| Q4 2024 | -$0.06 | +$0.65 |
AVAH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AVAH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $695.5M | +12% |
| Q2 2026 | $670.5M | +14% |
| Q1 2026 | $647.9M | +16% |
| Q4 2025 | $662.5M | +27% |
| Q3 2025 | $621.9M | +22% |
| Q2 2025 | $589.6M | +17% |
| Q1 2025 | $559.2M | +14% |
| Q4 2024 | $519.9M | +8.6% |
AVAH's revenue has grown year over year for 19 quarters in a row: $696M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +3.4 points |
| Q2 2026 | 12% | -1.7 points |
| Q1 2026 | 11% | +1.4 points |
| Q4 2025 | 11% | +1.9 points |
| Q3 2025 | 8.6% | +1.9 points |
| Q2 2025 | 14% | +6.2 points |
| Q1 2025 | 9.3% | +4.6 points |
| Q4 2024 | 8.8% | +2.7 points |
AVAH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AVAH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AVAH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $72.2M | +118% |
| Q2 2026 | $80.9M | +57% |
| Q1 2026 | $4.3M | +$13M |
| Q4 2025 | $49.7M | +271% |
| Q3 2025 | $33.2M | +13% |
| Q2 2025 | $51.6M | +2751% |
| Q1 2025 | -$8.6M | +$3.3M |
| Q4 2024 | $13.4M | +$16.4M |
AVAH has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
AVAH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +4.4M shares |
| 1 year | +3.1% | +7M shares |
| 3 years | +21% | +40.1M shares |
| 5 years | +29% | +51.5M shares |
| Available history | +27% | +49.1M shares |
AVAH has 229M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AVAH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AVAH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.5x | Elevated |
| Q2 2026 | 4.2x | High |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 4.1x | High |
| Q3 2025 | 4.8x | High |
| Q2 2025 | 5.3x | High |
| Q1 2025 | 6.7x | High |
| Q4 2024 | 8.0x | High |
AVAH's net debt is about 3.5 years of its operating earnings (EBITDA), down from 4.8 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AVAH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 69.3 | Neutral |
AVAH's weekly RSI is 58 (neutral) and its Stochastic is 69 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AVAH PE vs Healthcare Sector
| Metric | AVAH | Sector median | Relative |
|---|---|---|---|
| PE | 8.7x | 26x | 66% below |
| PE % | 27 | 36 | 9 pts below |
AVAH is trading at 8.7x earnings, a 66% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AVAH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 3.6% below |
| 20 week MA | $11.9 | 2.6% above |
| 50 week MA | $9.34 | 31% above |
| 100 week MA | $7.66 | 60% above |
| 200 week MA | $5.12 | 139% above |
AVAH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AVAH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.7 | $7.07 | -39% |
| 2022 | $7.07 | $0.77 | -89% |
| 2023 | $0.77 | $2.68 | +248% |
| 2024 | $2.68 | $4.66 | +74% |
| 2025 | $4.66 | $8.62 | +85% |
| 2026 YTD | $8.62 | $12.2 | +42% |
AVAH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.